The startup develops a biotechnology platform that utilizes RNA interference to create targeted therapies for metabolic diseases and obesity. Their treatments focus on reducing fat mass while preserving lean body mass, providing personalized solutions for patients with metabolic disorders.
Funding
$5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for metabolic diseases and obesity often fail to address the underlying genetic causes, leading to limited efficacy and the need for lifelong management. Existing therapies may also have undesirable side effects, such as loss of lean body mass, and require frequent dosing.
Solution
Canary Global is developing targeted RNAi therapies designed to address the root genetic causes of metabolic diseases and obesity. Their approach utilizes small interfering RNAs (siRNAs) to selectively silence genes involved in adipogenesis, energy expenditure, and metabolic regulation. By modulating these key pathways, Canary Global aims to promote fat loss while preserving lean body mass, improve metabolic health, and offer less frequent dosing schedules. The company's lead candidate, CCT-217, is engineered to transform white fat into metabolically active beige fat, enhancing energy expenditure and driving sustainable weight loss. Canary Global is also developing LNP-mRNA therapies to restore leptin signaling in children with Leptin Deficiency Disorder, addressing the underlying genetic cause of the condition.
Target Audience
The primary target audience includes individuals with metabolic disorders, obesity, rare genetic disorders, and neurological diseases, as well as clinicians and researchers in these fields.
Features
- siRNA therapeutics that target the endocannabinoid system to regulate appetite, metabolism, and fat storage
- Proprietary vectorized nanoantibody platform for targeted delivery of LNP-encapsulated mRNA to cells in the CNS and other tissues
- LNP-mRNA therapies that deliver mRNAs coding for therapeutic functional proteins
- Dual-combination therapy combining vectorized antibodies and functional transgene replacement for neurological disorders
- DigiGENE miRNA diagnostic platform using AI to read miRNA expression patterns for early disease detection
- REPROGRAM platform integrating human data analysis, AI, and siRNA technology for targeted gene silencing
- Chorus-siRNA technology platform exploiting synthetic gene regulatory networks for amplified therapeutic effects
- Development of novel biomarkers for predicting disease risk and monitoring responses to therapies